Amgen can continue marketing for now the firm’s Kanjinti (trastuzumab-anns) biosimilar in the US following a Court of Appeals ruling, ahead of a district court jury trial on trastuzumab intellectual property scheduled for next month.
Genentech, which markets the Herceptin original, has seen an appeals court affirm without comment a prior district court ruling denying the firm’s bid for a